N@N

CytoGenix, Inc. Moves Corporate Headquarters to New York City and Secures New Laboratory Space In Connecticut

_{//health-fitness.news-articles.net/content/2010/ .. secures-new-laboratory-space-in-connecticut.html}
^{Published in Health and Fitness on Thursday, September 23rd 2010 at 9:40 GMT by Market Wire}  

NEW YORK--([ BUSINESS WIRE ])--CytoGenix, Inc. (Pink Sheets:CYGX) announced that today its Board of Directors voted unanimously to move its Corporate Headquarters to New York, NY. Additionally it approved a commercial lease for Class A laboratory and office space in Middletown, CT where it will conduct its pharmaceutical research and testing procedures.

CytoGenix previously reported positive results of an animal study where mice were immunized with CYDBA507, CytoGenix's avian influenza vaccine candidate, which protected against lethal challenge with avian influenza virus. CYDBA507 is CytoGenixa™s avian influenza vaccine candidate which is built on CytoGenixa™s synDNA platform and expresses influenza virus type A/H5N1 HA and NA proteins.

Lex Cowsert, PhD, CEO of CYGX stated, aHaving our new Corporate Headquarters in New York City is an immeasurable benefit to CytoGenix. With our plan to have our company listed on the NASDAQ, we feel that being in the center of the financial world will enable CytoGenix to fully reach its goals of increasing shareholder value, that much sooner. Additionally with our new world class laboratory facilities in neighboring Connecticut, we are able to fully implement our plans in a much more efficient manner. Having laboratory facilities like we now have in Connecticut, will enable CytoGenix to meet the requirements for FDA approval of our product line quickly and efficiently.a

CytoGenix, Inc.

CytoGenix is a Nevada corporation traded under the symbol: CYGX.PK. CytoGenix is a biotechnology company developing biotechnology derived products for vaccines and therapeutic applications for human, agricultural and veterinary markets. As such, CytoGenix has access to a broad range of biological expertise that can be leveraged to identify, evaluate, develop and commercialize biologically based technologies for energy production.

Safe Harbor Statement

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Important factors, including general economic conditions, spending levels and other factors could cause actual results to differ materially from the Company's expectations.